I. Scharrer

发表

Inhibitors in PTP'S: A Retrospective Study in Germany

J. Oldenburg, W. Miesbach, C. Auer, 2006 .

Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges?

H. Ehrlich, I. Scharrer, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

W. Kreuz, S. Ehrenforth, I. Scharrer, 1992, The Lancet.

A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A

I. Scharrer, E. Aygören‐Pürsün, 1997, Thrombosis and Haemostasis.

Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion.

I. Scharrer, C. Kuhli, F. Koch, 2004, American journal of ophthalmology.

Visual Outcome after Treatment with Low-Dose Recombinant Tissue Plasminogen Activator or Hemodilution in Ischemic Central Retinal Vein Occlusion

I. Scharrer, F. Koch, C. Ohrloff, 1999, Ophthalmologica.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

P. Mannucci, Christine A. Lee, J. Goudemand, 2004, Blood.

Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden.

P. Kyrle, C. Mannhalter, I. Pabinger, 2000, The hematology journal : the official journal of the European Haematology Association.

Prevalence of Elevated Histidine-Rich Glycoprotein in Patients with Thrombophilia - a Study of 695 Patients

V. Hach-Wunderle, S. Ehrenforth, I. Scharrer, 1994, Thrombosis and Haemostasis.

Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood

R. Junker, W. Kreuz, U. Nowak‐Göttl, 1999, European Journal of Pediatrics.

Recurrent retinal vein occlusion in a patient with increased plasma levels of histidine-rich glycoprotein.

I. Scharrer, C. Kuhli, F. Koch, 2003, American journal of ophthalmology.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

B. Lämmle, G. Remuzzi, P. Kyrle, 1998, The New England journal of medicine.

Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome

J. Chapman, W. Miesbach, I. Scharrer, 2005, Journal of the Neurological Sciences.

Criteria for the Diagnosis of Lupus Anticoagulants: An Update

I. Scharrer, J. Brandt, D. Triplett, 1995, Thrombosis and Haemostasis.

Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: results from the Gutenberg Retinal Vein Occlusion Study.

N. Pfeiffer, P. Wild, H. Rossmann, 2019, Journal of hypertension.

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

P. Mannucci, C. Rothschild, A. Borel‐Derlon, 2007, Journal of thrombosis and haemostasis : JTH.

Prevalence of antiphospholipid antibodies in patients with neurological symptoms

D. Claus, W. Miesbach, I. Scharrer, 2006, Clinical Neurology and Neurosurgery.

The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism

A. Ganser, S. Ehrenforth, M. von Depka, 2003, Thrombosis and Haemostasis.

Coagulation disorders and the risk of retinal vein occlusion

I. Scharrer, L. Hattenbach, C. Kuhli-Hattenbach, 2009, Thrombosis and Haemostasis.

Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia

F. Rosendaal, G. Palareti, M. Makris, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A

W. Kreuz, M. Krause, I. Scharrer, 2006, Platelets.

Factor V Leiden (FV R506Q) in Families with Inherited Antithrombin Deficiency

P. Reitsma, F. Rosendaal, K. Bauer, 1996, Thrombosis and Haemostasis.

Thrombophilic Risk Parameters in Juvenile »Idiopathic« Stroke Patients

S. Ehrenforth, M. Krause, I. Scharrer, 2002 .

Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia

U. Nowak‐Göttl, S. Ehrenforth, I. Scharrer, 1998, European Journal of Pediatrics.

A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation.

A. Zeiher, D. Walter, V. Schächinger, 1999, Circulation.

[Phenprocoumon-induced necrotizing hepatitis].

S. Ehrenforth, I. Scharrer, G. Herrmann, 1995, Deutsche medizinische Wochenschrift.

Liver Damage Induced by Coumarin Anticoagulants

S. Ehrenforth, I. Scharrer, J. Schenk, 1999, Seminars in thrombosis and hemostasis.

Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies

W. Miesbach, I. Scharrer, R. Asherson, 2006, Clinical Rheumatology.

Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome.

D. Claus, W. Miesbach, I. Scharrer, 2005, Immunobiology.

ADAMTS13 In 4 Different VWF/VIII Concentrates and Its Impact on Therapy.

I. Scharrer, T. Falter, M. Qorraj, 2010 .

Fibrinolytic Therapy with Low-Dose Recombinant Tissue Plasminogen Activator in Retinal Vein Occlusion

I. Scharrer, C. Ohrloff, L. Hattenbach, 1998, Ophthalmologica.

Post-operative hematoma after surgery for intracranial meningiomas: Causes, avoidable risk factors and clinical outcome

J. Meixensberger, V. Seifert, A. Raabe, 2004, Neurological research.

The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia.

S. Ehrenforth, M. Krause, I. Scharrer, 1998, Blood.

No Evidence for Classic Thrombotic Microangiopathy in COVID-19

B. Lämmle, P. Galle, K. Lackner, 2021, Journal of clinical medicine.

Experience with Haemate P in von Willebrand's disease in adults.

I. Scharrer, E. Aygören‐Pürsün, T. Vigh, 1994, Haemostasis.

Haemate P in children with von Willebrand's disease.

W. Kreuz, I. Scharrer, B. Kornhuber, 1994, Haemostasis.

Increased incidence of thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae

V. Seifert, A. Raabe, S. Rohde, 2003, Neurological research.

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab

B. Lämmle, P. Wild, K. Lackner, 2018, Thrombosis and Haemostasis.

Prothrombotic risk factors in childhood stroke and venous thrombosis

W. Kreuz, I. Scharrer, C. Heller, 1999, European Journal of Pediatrics.

Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications.

M. Rafailovich, A. Henschen, D. Galanakis, 2014, Thrombosis research.

Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects

A. Henschen, D. Galanakis, W. Miesbach, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Cardiac and cerebral manifestations of the antiphospholipid syndrome

W. Miesbach, I. Scharrer, W. Miesbach, 2001, Hämostaseologie.

Kardiale und zerebrale Manifestationen bei Antiphospholipid-Syndrom

W. Miesbach, I. Scharrer, F. Jung, 2002, Zeitschrift für Kardiologie.

Antiphospholipidantikörpersyndrom@@@Antiphospholipid antibody syndrome

I. Scharrer, E. Scheuermann, H. Geiger, 1999 .

HLA genotype in patients with acquired haemophilia A

J. Oldenburg, A. Pavlova, H. Brackmann, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

HLA Profile in Acquired Hemophilia

E. Seifried, J. Oldenburg, A. Pavlova, 2005 .

Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease

E. Kretzschmar, E. Favaloro, I. Scharrer, 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The course of ADAMTS‐13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

W. Miesbach, C. Auer, M. Krause, 2005, British journal of haematology.

[Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin].

D. Peetz, W. Miesbach, I. Scharrer, 2003, Medizinische Klinik.

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

H. Brackmann, I. Scharrer, T. Abshire, 2000, Thrombosis and haemostasis.

Hereditary thrombophilia and fetal loss: a prospective follow‐up study

F. Rosendaal, G. Palareti, M. Makris, 2004, Journal of thrombosis and haemostasis : JTH.

Increased fetal loss in women with heritable thrombophilia

F. Rosendaal, C. Legnani, M. Makris, 1996, The Lancet.

Thrombophilic disorders in children with cerebral infarction

W. Kreuz, I. Scharrer, C. Heller, 1998, The Lancet.

Hepatocellular carcinoma in hemophilia

M. Colombo, P. Mannucci, D. Brettler, 1991, American journal of hematology.

Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates

J. Oldenburg, K. Kurnik, M. Depka, 2005, Annals of the New York Academy of Sciences.

Effects of human elastase on von Willebrand factor in highly purified factor VIII concentrate and in cryoprecipitate.

I. Scharrer, M. Kopeć, Z. Vigh, 1990, Thrombosis research.

Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer

I. Scharrer, J. Lusher, 2009, International journal of hematology.

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

H. Ehrlich, I. Scharrer, 2001 .

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow‐up

G. Auerswald, W. Kreuz, S. Ehrenforth, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Inquiry into the Significance of Constantly Raised FVIII Values as a Factor in Thrombophilia

C. Rabenstein, M. Krause, I. Scharrer, 2002 .

Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation

W. Miesbach, I. Scharrer, R. Asherson, 2004, Clinical Rheumatology.

Elevated Lp(a) Level and Heterozygous Factor V Mutation FV 1691 AG in a 26-Year-0ld Female with Ischemic Colitis

I. Scharrer, E. Aygören‐Pürsün, W. Gross, 2001 .

Five Novel Mutations in F13B Gene Resulting in Mild FXIII Deficiency

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2007 .

Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion.

I. Scharrer, L. Hattenbach, H. Baatz, 2008, American journal of ophthalmology.

Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[Lipoprotein(a): an indicator of risk in thromboembolic disease?].

W. März, I. Scharrer, W. Gross, 1990, Klinische Wochenschrift.

Multicentre Evaluation of Combined Prothrombotic Defects in Childhood Thromboembolism

W. Kreuz, U. Nowak‐Göttl, S. Ehrenforth, 1999 .

The Thrombostat 4000 A Sensitive Screening Test for von Willebrand's Disease

I. Scharrer, V. Kretschmer, U. Budde, 1995, Seminars in Thrombosis & Hemostasis.

Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease.

J. Griffin, F. España, V. Vicente, 1990, Thrombosis research.

High prevalence of resistance to APC in young patients with retinal vein occlusion

I. Scharrer, C. Kuhli, F. Koch, 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism.

A. Ganser, U. Nowak‐Göttl, S. Ehrenforth, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Prothrombin Frankfurt: A Dysfunctional Prothrombin Characterized by Substitution of Glu-466 by Ala

S. J. Degen, I. Scharrer, S. McDowell, 1995, Thrombosis and Haemostasis.

Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven®): a single centre experience

I. Scharrer, K. Hochmuth, L. Hovy, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Depression and cognitive deficits as long‐term consequences of thrombotic thrombocytopenic purpura

B. Lämmle, M. Beutel, K. Lackner, 2017, Transfusion.

Apolipoprotein (a) concentrations are not related to the risk of venous thrombosis

W. März, I. Scharrer, M. Trommlitz, 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin’s lymphoma

W. Miesbach, I. Scharrer, R. Asherson, 2006, Clinical Rheumatology.

Identification of Thrombin Antibodies in Patients with Antiphospholipid Syndrome

T. Matthias, W. Miesbach, I. Scharrer, 2005, Annals of the New York Academy of Sciences.

Clinical Manifestations of Patients with Highly Elevated Anticardiolipin Antibodies

W. Miesbach, I. Scharrer, G. Asmelash, 2004 .

Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report.

H. Brodt, S. Koschmieder, W. Miesbach, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Autoimmune disorders in patients with idiopathic thrombotic thrombocytopenic purpura

I. Scharrer, M. John, 2012, Hämostaseologie.

33rd Hemophilia Symposium

W. Schramm, I. Scharrer, 2004, Springer Berlin Heidelberg.

Regression of deep vein thrombosis by i.v.-administration of a low molecular weight heparin--results of a pilot study.

I. Scharrer, E. Lindhoff‐Last, H. Breddin, 1994, Thrombosis research.

A Role for Toll-Like Receptor Mediated Signals in Neutrophils in the Pathogenesis of the Anti-Phospholipid Syndrome

H. Schild, K. Lackner, I. Scharrer, 2012, PloS one.

Long term outcome and sequelae in patients after acute thrombotic thrombo cytopenic purpura episodes *

I. Scharrer, T. Falter, K. Alber, 2017 .

Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse

I. Scharrer, Jennifer Mai Falk, 2016, Transfusion.

Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes

I. Scharrer, T. Falter, K. Alber, 2013, Hämostaseologie.

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia

F. Heidel, D. Lipka, C. Huber, 2007, Thrombosis and Haemostasis.

Is there a Correlation between vWF-cleaving Protease-Activity, vWF:Ag, Clinical Course and Number of Relapses in 15 Patients with TTP?

M. Krause, I. Scharrer, M. Böhm, 2003 .

Changes of coagulation parameters during high altitude expedition.

L. Risch, A. Huber, T. Merz, 2010, Swiss medical weekly.

Antiphospholipidantikörpersyndrom

I. Scharrer, E. Scheuermann, H. Geiger, 1999, Medizinische Klinik.

The von willebrand-syndrome

I. Scharrer, 1983, Blut.

Post-trauma coagulation and fibrinolysis in children suffering from severe cerebro-cranial trauma

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1999, European journal of pediatrics.

Investigation of the Tendency to Bleeding in Patients with low Activity of Plasminogen Activator Inhibitor-1 (PAI-1)

W. Miesbach, I. Scharrer, T. Vigh, 2005 .

Malignancy is not Associated with Decreased ADAMTS-13 Activity in Patients with Brain Tumors

I. Scharrer, R. Gerlach, M. Böhm, 2004 .

Von-Willebrand Factor Cleaving Protease (ADAMTS-13) Activity in Various Thrombotic, Hemolytic and Autoimmune Disorders

W. Miesbach, M. Krause, I. Scharrer, 2004 .

ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis.

W. Beecken, I. Scharrer, R. Gerlach, 2003, Thrombosis research.

Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13)

I. Scharrer, M. Böhm, T. Vigh, 2002, Annals of Hematology.

Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany.

S. Staszewski, H. Doerr, A. Berger, 1995, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age].

I. Scharrer, L. Hattenbach, M. Lüchtenberg, 2008, Klinische Monatsblatter fur Augenheilkunde.

Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy

I. Scharrer, L. Hattenbach, M. Lüchtenberg, 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

Thromboseprophylaxe mit Aspirin?

I. Scharrer, M. Schepping, K. Breddin, 1969, Klinische Wochenschrift.

[Therapy of thromboembolic processes using acetylsalicylic acid. Action mechanism and clinical aspects].

I. Scharrer, 1971, Der Radiologe.

Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications.

G. Nuovo, D. Galanakis, I. Scharrer, 1996, Thrombosis research.

Leg ulcers in Klinefelter's syndrome – further evidence for an involvement of plasminogen activator inhibitor‐1

T. Zollner, W. Boehncke, R. Kaufmann, 1997, The British journal of dermatology.

European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients

M. Torchet, C. Rothschild, H. Brackmann, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A

M. Ragni, H. Brackmann, I. Scharrer, 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

Mutations in the VKORC1 Gene Cause Warfarin Resistance, Warfarin Sensitivity and Combined Deficiency of Vitamin K Dependent Coagulation Factors.

E. Seifried, J. Oldenburg, C. Geisen, 2004 .

ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis

H. Schild, K. Jurk, S. Reuter, 2017, Scientific Reports.

Early and rapid Diagnosis of acute TTP by Measuring Activity of von-Willebrand Factor cleaving Metalloprotease (ADAMTS13): A Case Report

I. Scharrer, C. Betz, M. Böhm, 2003 .

Lack of evidence for increased inhibitor incidence in patients switched from plasma‐derived to recombinant factor VIII

H. Ehrlich, I. Scharrer, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Transient inhibitors in the Recombinate PUP study.

I. Scharrer, G. Bray, J. Gill, 2000, Thrombosis and haemostasis.

Investigation of a Congenital Abnormal Plasminogen, Frankfurt I, and Its Relationship to Thrombosis

I. Scharrer, K. Robbins, R. Wohl, 1986, Thrombosis and Haemostasis.

Protein A immunoadsorption therapy for refractory, mitomycin C–associated thrombotic microangiopathy

M. Neurath, S. Kasper, C. Huber, 2007, Transfusion.

Total hip replacement in patients with severe bleeding disorders

I. Scharrer, A. Kurth, L. Hovy, 2007, International Orthopaedics.

Cross‐cultural development and psychometric evaluation of a patient‐reported health‐related quality of life questionnaire for adults with haemophilia

M. Bullinger, R. Klamroth, W. Schramm, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-Term Results After Total Knee and Total Hip Replacement in Hemophilic Arthropathy

I. Scharrer, S. Müller, L. Hovy, 2001 .

Orthopaedic surgery in hemophilic patients

I. Scharrer, H. Willert, W. Ewald, 2004, Archives of orthopaedic and traumatic surgery.

Incidence of inhibitors in haemophiliacs. A review of the literature.

I. Scharrer, O. Neutzling, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

I. Scharrer, L. Hoyer, L. Hoyer, 2001, Thrombosis research.

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

I. Scharrer, G. Bray, I. Nilsson, 1997, Blood.

Treatment patterns and cost‐of‐illness of severe haemophilia in patients with inhibitors in Germany

K. Kurnik, W. Schramm, G. Auerswald, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical Trials of Recombinant Factor VIII

P. Mannucci, C. Kessler, H. Kingdon, 1991 .

Total hip replacement in patients with severe bleeding disorders. A 30 years single center experience.

I. Scharrer, A. Kurth, L. Hovy, 2007, International orthopaedics.

Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy

H. Brackmann, I. Scharrer, T. Abshire, 2000, Thrombosis and Haemostasis.

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/ Humate®‐P: History and clinical performance

P. Mannucci, G. Auerswald, M. Franchini, 2008, European journal of haematology. Supplementum.

Women with von Willebrand disease.

I. Scharrer, 2004, Hamostaseologie.

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

P. Mannucci, A. Borel‐Derlon, J. Goudemand, 2005, Journal of thrombosis and haemostasis : JTH.

Risk of Gastrointestinal Bleeding Associated with Helicobacter pylori Infection in Patients with Hemophilia or von Willebrand’s Syndrome

C. Dietrich, B. Braden, B. Lembcke, 1998, Helicobacter.

Valproate Therapy Induces von Willebrand Disease Type I

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1992, Epilepsia.

Congenital plasminogen deficiency with an abnormal plasminogen: Frankfurt II, dysplasminogenaemia-hypoplasminogenaemia

V. Hach-Wunderle, I. Scharrer, K. Robbins, 1991 .

Cathepsin G can be responsible for von Willebrand factor degradation in whole blood during storage

I. Scharrer, M. Kopeć, M. Jeleńska, 1995, Transfusion Medicine.

Fibrinogen does not protect von Willebrand factor against proteolysis by human cathepsin G.

I. Scharrer, M. Kopeć, Z. Vigh, 1991, Thrombosis research.

Protein C inhibitor is expressed in tubular cells of human kidney.

J. Griffin, J. A. Fernandez, D. Loskutoff, 1994, The Journal of clinical investigation.

Experience with KOGENATE® Bayer in surgical procedures

I. Scharrer, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

J. Windyga, S. Lalezari, U. Martinowitz, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia B and other bleeding disorders

J. Oldenburg, S. Rost, V. Ivaškevičius, 2000 .

Diagnosis and therapy of coagulation disorders in operative orthopedics

I. Scharrer, 1999, Der Orthopäde.

[Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients].

I. Scharrer, A. Kurth, G. Ludwig, 1999, Der Orthopade.

Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.

G. Auerswald, W. Kreuz, S. Ehrenforth, 1994, Thrombosis and haemostasis.

Major Orthopedic Reconstructions in an Inhibitor Patient — A Case Report

W. Miesbach, M. Krause, I. Scharrer, 2005 .

Evaluation of Thrombotic Events in Hemophiliacs Undergoing Major Orthopedic Surgery Without Thrombosis Prophylaxis

C. Auer, M. Krause, I. Scharrer, 2005 .

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Andreas Fregin, T. Strom, E. Seifried, 2004, Nature.

Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy.

H. Ehrlich, J. Oldenburg, R. Schwaab, 1998, Annals of hematology.

Factor VIII inhibitors in haemophiliacs

W. Kreuz, S. Ehrenforth, I. Scharrer, 1992, The Lancet.

Acquired haemophilia caused by non-haemophilic factor VIII gene variants

A. Ganser, W. Miesbach, A. Tiede, 2010, Annals of Hematology.

Increased frequency of the CTLA‐4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls

T. Wienker, A. Hoerauf, J. Oldenburg, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients

M. Krause, I. Scharrer, A. Hahn, 2006 .

Screening of F.VIII:C Antibodies by an Enzyme‐Linked Immunosorbent Assay

W. Kreuz, S. Ehrenforth, I. Scharrer, 1994, Vox sanguinis.

Acquired Inhibitors Against Factor VIII and Factor IX

I. Scharrer, 1997 .

Haemophilia A

S. Rost, V. Ivaškevičius, J. Luboshitz, 2000 .

The need for highly purified products to treat hemophilia B.

I. Scharrer, 1995, Acta haematologica.

A Review of its Use in Patients with Haemophilia A

R. Yang, I. Scharrer, Wolters Kluwer, 2008 .

33rd Hemophilia Symposium : Hamburg, 2002

W. Schramm, I. Scharrer, Hämophilie-Symposion, 2004 .

Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy

D. Galanakis, W. Miesbach, I. Scharrer, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

32nd Hemophilia Symposium

W. Schramm, I. Scharrer, 2003, Springer Berlin Heidelberg.

Identification of Inhibitor Epitopes in Acquired Hemophilia by Phage Display

C. Königs, W. Kreuz, M. Krause, 2007 .

36th Hemophilia Symposium Hamburg 2005

W. Schramm, I. Scharrer, 2007 .

Products used to Treat Hemophilia: Evolution of Treatment for Hemophilia A and B

I. Scharrer, T. Becker, 2007 .

[Haemophilia treatment centres in Germany].

H. Pollmann, B. Eifrig, H. Lenk, 2012, Hamostaseologie.

Prevalence, pathophysiology, diagnosis, and treatment of Willebrand syndrome in orthopedic-trauma patients

I. Scharrer, A. Kurth, G. Ludwig, 1999, Der Orthopäde.

The risk of postoperative hemorrhage after intracranial surgery following early Nadroparin administration - results of a prospective study

V. Seifert, A. Raabe, I. Scharrer, 2003 .

Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report.

V. Seifert, A. Raabe, G. Marquardt, 2002, Journal of neurosurgery.

Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels

K. Jurk, S. Subramaniam, C. Reinhardt, 2017, PloS one.

Identification of platelet function defects by multi-parameter assessment of thrombus formation

Rachel Cavill, Richard W. Farndale, A. Schulz, 2014, Nature Communications.

Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases

V. Seifert, A. Raabe, J. Beck, 2003, Neurological research.

Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys).

H. Watzke, I. Scharrer, P. Turecek, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Reduced plasma levels of coagulation factors in relation to prostate cancer

J. Binder, D. Jonas, W. Bentas, 2002, The Prostate.

Tissue Fibrinolytic Activity in Different Types of Varicose Veins

I. Scharrer, N. Blees, V. Hach, 1986, Angiology.

Leg Ulcer Patients: No Decreased Fibrinolytic Response but White Cell Trapping after Venous Occlusion of the Upper Limb

O. Kresse, V. Hach-Wunderle, I. Scharrer, 1992 .

A FATAL CASE OF SNAKE BITE DUE TO THELOTORNIS KIRTLANDII

D. Mebs, I. Scharrer, H. Hauk, 1978 .

The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma

V. Seifert, C. Senft, M. Forster, 2010, Journal of Clinical Neuroscience.

PädiatrieEvaluation of Laboratory Tests Used to Monitor 1 -Deamino-8-D-Arginine Vasopressin Infusion: Preliminary Results

A. Grohmann, I. Scharrer, B. Zieger, 1997 .

The Frequency of Type I Heterozygous Protein S and Protein C Deficiency in 141 Unrelated Young Patients with Venous Thrombosis

J. Griffin, I. Scharrer, C. Gladson, 1988, Thrombosis and Haemostasis.

Retinal vein occlusion associated with antithrombin deficiency secondary to a novel G9840C missense mutation.

I. Scharrer, C. Kuhli, L. Hattenbach, 2006, Archives of ophthalmology.

Retinal Vein Occlusion Associated With Antithrombin Deficiency Secondary to a Novel G 9840 C Missense Mutation

I. Scharrer, C. Kuhli, L. Hattenbach, 2006 .

Interaction of factor V Leiden with inherited anti-thrombin deficiency

P. Reitsma, J. Vandenbroucke, F. Rosendaal, 1995 .

Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication

B. Lämmle, A. Gabelmann, S. Eichinger, 1994, Thrombosis and Haemostasis.

Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)

F R Rosendaal, F E Preston, F. Rosendaal, 2005, Journal of thrombosis and haemostasis : JTH.

Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema

J. Oldenburg, K. Bork, W. Kreuz, 2006 .

Mutation Analysis of the C1 Inhibitor Gene

J. Oldenburg, K. Bork, W. Kreuz, 2005 .

Severe factor V deficiency presenting as subdural haematoma in the newborn

B. Zabel, W. Kreuz, S. Ehrenforth, 1998, European Journal of Pediatrics.

Procoagulant activity during viral infections.

S. Subramaniam, I. Scharrer, 2018, Frontiers in bioscience.

Frequencies of GB virus C/hepatitis G virus genomes and of specific antibodies in German risk and non‐risk populations

S. Staszewski, E. Seifried, J. Löwer, 1997, Journal of medical virology.

Case Report of a FXIII Inhibitor in a 77-year-old Patient

W. Miesbach, C. Auer, I. Scharrer, 2006 .

Infection with hepatitis G virus in immunoglobulin recipients

H. Doerr, A. Berger, I. Scharrer, 1997, The Lancet.

Induction of von Willebrand disease type I by valproic acid

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1990, The Lancet.

Follow‐up of four HIV‐infected individuals after administration of hepatitis C virus and GBV‐C/hepatitis G virus contaminated intravenous immunoglobulin: Evidence for HCV but not for GBV‐C/HGV transmission

H. Doerr, A. Berger, I. Scharrer, 1997, Journal of medical virology.

Unusual A alpha 16Arg-->Cys dysfibrinogenaemic family: absence of normal A alpha-chains in fibrinogen from two of four heterozygous siblings.

D. Galanakis, I. Scharrer, S. Spitzer, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.

S. Ehrenforth, I. Scharrer, C. Ruppert, 1997, Cancer detection and prevention.

Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage

A. von Eckardstein, A. Heinecke, R. Klamroth, 2005, Thrombosis and Haemostasis.

Patterns of changes of anti‐ADAMTS13 after plasma exchange

I. Scharrer, F. Scheiflinger, P. Mannucci, 2006, Journal of thrombosis and haemostasis : JTH.

The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura

I. Scharrer, W. Hitzler, M. John, 2012, Annals of Hematology.

Post-trauma coagulation and fibrinolysis in children suffering from severe cerebro-cranial trauma

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1970, European Journal of Pediatrics.

Factor V Inhibitor and Anti-Phospholipid Antibodies after Treatment with Ciprofloxacin

W. Miesbach, I. Scharrer, B. Bühler, 2003 .

RETINAL VEIN OCCLUSION AND LOW-DOSE FIBRINOLYTIC THERAPY (R.O.L.F.): A Prospective, Randomized, Controlled Multicenter Study of Low-Dose Recombinant Tissue Plasminogen Activator Versus Hemodilution in Retinal Vein Occlusion

I. Scharrer, C. Ohrloff, L. Hattenbach, 2009, Retina.

Acquired Activated Protein C-Resistance in Patients with Lupus Anticoagulants

K. Radtke, S. Ehrenforth, I. Scharrer, 1995, Thrombosis and Haemostasis.

Familial thrombophilia and lifetime risk of venous thrombosis

F R Rosendaal, F E Preston, F. Rosendaal, 2004, Journal of thrombosis and haemostasis : JTH.

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.

B. Lämmle, G. Remuzzi, P. Mannucci, 2005, Blood.

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.

A. Ganser, M. Depka, U. Nowak‐Göttl, 2000, Blood.

Chronic thrombocytopenia in an immunodeficient patient with hemophilia A

I. Scharrer, C. Mueller-Eckhardt, L. Bergmann, 1985, Blut.

Treatment of Intracerebral Hemorrhage Related to Anticoagulation Therapy Since Advent of Computer-Tomography: Report of Eight Cases

H. Hacker, I. Scharrer, W. Steudel, 1980 .

Central Retinal Vein Occlusion and Nonarteritic Ischemic Optic Neuropathy in 2 Patients with Mild Iron Deficiency Anemia

I. Scharrer, F. Koch, L. Hattenbach, 2001, Ophthalmologica.

Congenital Deficiency of Plasminogen and Its Relationship to Venous Thrombosis

V. Hach-Wunderle, I. Scharrer, R. Lottenberg, 1988, Thrombosis and Haemostasis.

Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany

P. Wernet, E. Seifried, R. Kurth, 1985, Klinische Wochenschrift.

[Bleeding and coagulation disorders in tonsillectomies].

I. Scharrer, K. Papaspyrou, T. Mewes, 2012, HNO.

CLINICAL CURE OF HAEMOPHILIA A BY LIVER TRANSPLANTATION

I. Scharrer, A. Encke, C. Hottenrott, 1988, The Lancet.

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism

A. Ganser, M. Depka, U. Nowak‐Göttl, 2000 .

The Importance of Pre-Analytic Conditions on the Determination of VWF Parameters

C. Rabenstein, I. Scharrer, B. Putz, 2005 .

Scientific and Standardization Committee Communications Criteria for the Diagnosis of Lupus Anticoagulants: An Update On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH

I. Scharrer, J. Brandt, D. Triplett, 2018 .

Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A

F. Rosendaal, C. Mannhalter, I. Pabinger, 2004, Journal of thrombosis and haemostasis : JTH.

A Functional Assay Suggests that Heterodimers Exist in Two C-Terminal γ-Chain Dysfibrinogens: Matsumoto I and Vlissingen/Frankfurt IV

S. Lord, D. Galanakis, F. Terasawa, 2000, Thrombosis and Haemostasis.

Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis.

V. Hach-Wunderle, I. Scharrer, K. Robbins, 1988, Haemostasis.

In-vitro-Blutungstest (IVBT) als sensitiver Screeningstest beim Von-Willebrand-Syndrom (VWS)

I. Scharrer, V. Kretschmer, U. Budde, 1996 .

Therapeutic Impact of Orthotopic Liver Transplantation on Disorders of Hemostasis

I. Scharrer, P. Fischbach, Petra Fischbach, 1993, Seminars in thrombosis and hemostasis.

ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis

H. Schild, K. Jurk, S. Reuter, 2017, Scientific Reports.

Isolation of lipoprotein (a) using the regenerate of a dextran sulfate cellulose LDL apheresis system.

W. März, I. Scharrer, W. Gross, 1994, Protein expression and purification.

[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].

A. Ganser, W. Kreuz, S. Ehrenforth, 1999, Deutsche medizinische Wochenschrift.

Lack of inhibitor to monoclonal-antibody purified FVIII concentrate

I. Scharrer, W. Mondorf, 1990, The Lancet.

INCIDENCE OF DEFECTIVE T-PA RELEASE IN 158 UNRELATED YOUNG PATIENTS WITH VENOUS THROMBOSIS IN COMPARISON TO PC-, PS-, AT III-, FIBRINOGEN- AND PLASMINOGENDEFICIENCY

V. Hach-Wunderle, I. Scharrer, C. Kuhn, 1987, Thrombosis and Haemostasis.

[Selective thrombophilia screening of young patients with retinal vein occlusion].

I. Scharrer, L. Hattenbach, M. Lüchtenberg, 2009, Klinische Monatsblatter fur Augenheilkunde.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

B. Lämmle, G. Remuzzi, P. Kyrle, 1998 .

Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A

J. Oldenburg, S. Rost, R. Schwaab, 2001 .

The Occurrence of Factor VIII Inhibitor in a Patient with Mild Hemophilia A - During Treatment with Interferon for Chronic Hepatitis C

W. Miesbach, C. Auer, I. Scharrer, 2007 .

Bleeding Tendency of Carriers of Hemophilia A - Dependent on the Age of the Carriers?

J. Oldenburg, W. Miesbach, I. Scharrer, 2005 .

Bleeding Symptoms in Carriers of Hemophilia A — Association to the Factor VIII Gene Mutation?

J. Oldenburg, W. Miesbach, I. Scharrer, 2004 .

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

I. Scharrer, Scharrer, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.

G. Auerswald, W. Schramm, W. Kreuz, 1989, The New England journal of medicine.

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

P. Mannucci, D. Brettler, M. Hilgartner, 1990, The New England journal of medicine.

Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura

B. Lämmle, K. Lackner, I. Scharrer, 2014, Hämostaseologie.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

P. Mannucci, Christine A. Lee, J. Goudemand, 2004, Blood.

Prevalence of a 23bp Insertion in Exon 3 of the Endothelial Cell Protein C Receptor Gene in Venous Thrombophilia

A. Ganser, M. Depka, S. Ehrenforth, 2001, Thrombosis and Haemostasis.

Clinical Observations, Interventions, and Therapeutic Trials

P. Mannucci, Christine A. Lee, J. Goudemand, 2000 .

Release of von Willebrand Factor after Venous Occlusion – The Importance of Standardization of Venous Occlusion Tests

I. Scharrer, Zsolt Vigh, 1993, Thrombosis and Haemostasis.

Do Statins Increase the Homocysteine Level

L. Rössig, C. Rabenstein, I. Scharrer, 2002 .

Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII

C. Auer, M. Krause, I. Scharrer, 2006 .

Haemophilia A

S. Rost, V. Ivaškevičius, J. Luboshitz, 2000 .

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies

W. Kreuz, H. Brackmann, G. Auerswald, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

229 Family study of juvenile patients with recurrent venous thrombosis and abnormal fibrinolysis

V. Hach-Wunderle, I. Scharrer, E. Aygören, 1988 .

FREQUENCY AND CLINICAL MANIFESTATIONS OF CONGENITAL PLASMINOGEN AND FIBRINOGEN DEFICIENCY COMPARED TO AT III-, PC- AND PS- DEFICIENCY IN PATIENTS SUFFERING FROM THROMBOSES

V. Hach-Wunderle, I. Scharrer, K. Robbins, 1988 .

Selektives Thrombophiliescreening junger Patienten mit venösen retinalen Gefäßverschlüssen

I. Scharrer, M. Lüchtenberg, C. Kuhli‐Hattenbach, 2009, Klinische Monatsblätter für Augenheilkunde.

Heparin cofactor II deficiency in central retinal vein occlusion.

C. Klais, I. Scharrer, Hattenbach Lo, 1998, Acta ophthalmologica Scandinavica.

[Front-loading rt PA thrombolytic therapy in central or venous branch occlusions of the retina].

I. Scharrer, C. Ohrloff, L. Hattenbach, 1994, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura

B. Lämmle, M. Beutel, K. Lackner, 2021, Journal of clinical medicine.

Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin

W. Miesbach, I. Scharrer, M. Boehm, 2005, Thrombosis and Haemostasis.

Successful Liver Transplantation in a Patient with Anti-Thrombocyte Antibodies and Severe Hemophilia A

W. Bechstein, W. Miesbach, I. Scharrer, 2007 .